Medical marijuana advocates and bureaucrats from regulatory agencies around the world have both been awaiting a statement on the risks and benefits of cannabidiol (CBD) from the World Health Organization's Expert Committee on Drug Dependence (ECDD). Now the assessment on the non-psychoactive cannabinoid is in, and it is encouraging news for those who have been hoping for its removal from Schedule 1, the international designation for drugs with no therapeutic value but high potential for abuse.
Recent comments
12 weeks 3 days ago
16 weeks 4 days ago
18 weeks 1 day ago
18 weeks 2 days ago
30 weeks 4 days ago
36 weeks 2 days ago
47 weeks 2 days ago
48 weeks 2 days ago
49 weeks 6 days ago
50 weeks 2 days ago